Research programme: invariant natural killer T-cells therapeutics - SalvaRxAlternative Names: iNKT therapeutics - SalvaRx
Latest Information Update: 30 Mar 2016
At a glance
- Originator Ludwig Institute for Cancer Research; University of Oxford
- Developer SalvaRx
- Class Immunotherapies; Lipids
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer